What type of lymphoma is Tafasitamab mainly used to treat? Indications introduction

Tafasitamab is a humanized anti-CD19 monoclonal antibody originally developed by MorphoSys The company developed it in combination with lenalidomide (Lenalidomide) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) adult patients, especially those who are not suitable for autologous hematopoietic stem cell transplantation (ASCT). Such patients usually experience treatment failure with first-line rituximab-containing chemotherapy regimens and have poor prognosis. The Tafasitamab + lenalidomide regimen provides a new, immune-oriented, non-chemotherapy option.

In June 2025 June, the U.S. FDA approved the expansion of the indications of tanxituzumab to be used in combination with lenalidomide and rituximab for treatment**Adult patients with relapsed/refractory follicular lymphoma (FL)**. This marks the continued expansion of the drug’s application in the field of CD19positiveB cell lymphoma, especially in relapsed low-grade lymphoma, which has shown good tolerability and response rate, providing more immunotherapy options for clinical treatment.

Tafasitamabtargets the CD19 molecule, which is a transmembrane glycoprotein widely expressed on B cells. In most B cell lymphomas (such as DLBCL, FL , mantle cell lymphoma, etc.), CD19 continues to be highly expressed, so Tafasitamab has a wide range of theoretical adaptability. Clinical research is currently exploring the possibility of its combined use with other immunotherapies (such as CAR-T, PD-1 inhibitors), and is expected to be expanded to more types of B cell malignancies in the future.

Although currentlyTafasitamab is mainly used for second-line treatment of relapsed or refractory patients, but studies have tried to use it in combination with other drugs for patients with newly diagnosed DLBCL, or for maintenance treatment to extend progression-free survival (PFS). If more data support is obtained in the future, its indications may be further expanded and may even replace traditional chemotherapy in some patients. For patients with CD19positive B cell lymphoma, Tafasitamab is gradually becoming an important new treatment option.

Reference materials:https://www.fda.gov/drugs/